Literature DB >> 17108039

Inhibition of heavy chain and beta2-microglobulin synthesis as a mechanism of major histocompatibility complex class I downregulation during Epstein-Barr virus replication.

Andre Ortlieb Guerreiro-Cacais1, Mehmet Uzunel, Jelena Levitskaya, Victor Levitsky.   

Abstract

The mechanisms of major histocompatibility complex (MHC) class I downregulation during Epstein-Barr virus (EBV) replication are not well characterized. Here we show that in several cell lines infected with a recombinant EBV strain encoding green fluorescent protein (GFP), the virus lytic cycle coincides with GFP expression, which thus can be used as a marker of virus replication. EBV replication resulted in downregulation of MHC class II and all classical MHC class I alleles independently of viral DNA synthesis or late gene expression. Although assembled MHC class I complexes, the total pool of heavy chains, and beta2-microglobulin (beta2m) were significantly downregulated, free class I heavy chains were stabilized at the surface of cells replicating EBV. Calnexin expression was increased in GFP+ cells, and calnexin and calreticulin accumulated at the cell surface that could contribute to the stabilization of class I heavy chains. Decreased expression levels of another chaperone, ERp57, and TAP2, a transporter associated with antigen processing and presentation, correlated with delayed kinetics of MHC class I maturation. Levels of both class I heavy chain and beta2m mRNA were reduced, and metabolic labeling experiments demonstrated a very low rate of class I heavy chain synthesis in lytically infected cells. MHC class I and MHC class II downregulation was mimicked by pharmacological inhibition of protein synthesis in latently infected cells. Our data suggest that although several mechanisms may contribute to MHC class I downregulation in the course of EBV replication, inhibition of MHC class I synthesis plays the primary role in the process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17108039      PMCID: PMC1797541          DOI: 10.1128/JVI.01999-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

Review 1.  In search of the 'missing self': MHC molecules and NK cell recognition.

Authors:  H G Ljunggren; K Kärre
Journal:  Immunol Today       Date:  1990-07

2.  Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells.

Authors:  R Khanna; L Cooper; N Kienzle; D J Moss; S R Burrows; K K Khanna
Journal:  J Immunol       Date:  1997-12-15       Impact factor: 5.422

3.  Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect.

Authors:  X Wang; L M Hutt-Fletcher
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

4.  Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells.

Authors:  T Frisan; Q J Zhang; J Levitskaya; M Coram; M G Kurilla; M G Masucci
Journal:  Int J Cancer       Date:  1996-10-09       Impact factor: 7.396

5.  Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products.

Authors:  N J Stam; H Spits; H L Ploegh
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

6.  The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol.

Authors:  E J Wiertz; T R Jones; L Sun; M Bogyo; H J Geuze; H L Ploegh
Journal:  Cell       Date:  1996-03-08       Impact factor: 41.582

7.  The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B.

Authors:  D E Gutsch; E A Holley-Guthrie; Q Zhang; B Stein; M A Blanar; A S Baldwin; S C Kenney
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

8.  The HCMV gene products US11 and US2 differ in their ability to attack allelic forms of murine major histocompatibility complex (MHC) class I heavy chains.

Authors:  R P Machold; E J Wiertz; T R Jones; H L Ploegh
Journal:  J Exp Med       Date:  1997-01-20       Impact factor: 14.307

9.  The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase.

Authors:  E A Gustafson; A C Chillemi; D R Sage; J D Fingeroth
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules.

Authors:  O Mandelboim; H T Reyburn; M Valés-Gómez; L Pazmany; M Colonna; G Borsellino; J L Strominger
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

View more
  10 in total

Review 1.  Viral proteins interfering with antigen presentation target the major histocompatibility complex class I peptide-loading complex.

Authors:  Gustav Røder; Linda Geironson; Iain Bressendorff; Kajsa Paulsson
Journal:  J Virol       Date:  2008-04-30       Impact factor: 5.103

2.  A deneddylase encoded by Epstein-Barr virus promotes viral DNA replication by regulating the activity of cullin-RING ligases.

Authors:  Stefano Gastaldello; Sebastian Hildebrand; Omid Faridani; Simone Callegari; Mia Palmkvist; Claudia Di Guglielmo; Maria G Masucci
Journal:  Nat Cell Biol       Date:  2010-02-28       Impact factor: 28.824

3.  The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function.

Authors:  Jianmin Zuo; Wendy Thomas; Daphne van Leeuwen; Jaap M Middeldorp; Emmanuel J H J Wiertz; Maaike E Ressing; Martin Rowe
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

4.  The Epstein-Barr virus miR-BHRF1-1 targets RNF4 during productive infection to promote the accumulation of SUMO conjugates and the release of infectious virus.

Authors:  Jinlin Li; Simone Callegari; Maria G Masucci
Journal:  PLoS Pathog       Date:  2017-04-17       Impact factor: 6.823

5.  The Epstein-Barr virus nuclear antigen-1 upregulates the cellular antioxidant defense to enable B-cell growth transformation and immortalization.

Authors:  Jiayu Wang; Noemi Nagy; Maria G Masucci
Journal:  Oncogene       Date:  2019-09-11       Impact factor: 9.867

Review 6.  Epstein-Barr Virus and Multiple Sclerosis.

Authors:  Gunnar Houen; Nicole Hartwig Trier; Jette Lautrup Frederiksen
Journal:  Front Immunol       Date:  2020-12-17       Impact factor: 7.561

Review 7.  Immune responses to Epstein-Barr virus: molecular interactions in the virus evasion of CD8+ T cell immunity.

Authors:  Martin Rowe; Jianmin Zuo
Journal:  Microbes Infect       Date:  2010-02-01       Impact factor: 2.700

8.  Caspase-1 promotes Epstein-Barr virus replication by targeting the large tegument protein deneddylase to the nucleus of productively infected cells.

Authors:  Stefano Gastaldello; Xinsong Chen; Simone Callegari; Maria G Masucci
Journal:  PLoS Pathog       Date:  2013-10-10       Impact factor: 6.823

9.  A molecular link between malaria and Epstein-Barr virus reactivation.

Authors:  Arnaud Chêne; Daria Donati; André Ortlieb Guerreiro-Cacais; Victor Levitsky; Qijun Chen; Kerstin I Falk; Jackson Orem; Fred Kironde; Mats Wahlgren; Maria Teresa Bejarano
Journal:  PLoS Pathog       Date:  2007-06       Impact factor: 6.823

10.  In vitro Studies and Clinical Observations Imply a Synergistic Effect Between Epstein-Barr Virus and Dengue Virus Infection.

Authors:  Xiao-Mei Deng; Ling-Zhai Zhao; Xue-Ying Liang; Dan Li; Lei Yu; Fu-Chun Zhang; Hua Zhang; Zhong-Yu Liu; Pei Xu
Journal:  Front Microbiol       Date:  2021-06-18       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.